Lexicon Pharmaceuticals

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public, Subsidiary

Established: 1995-01-01

Employees: 285

Market Cap: $621.7M

Website: http://www.lexpharma.com

Introduction: Lexicon Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. Its drug candidates include: LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain, and Sotagliflozin, a treatment for heart failure and type 1 diabetes. The company was founded by Brian P. Zambrowicz and Arthur T. Sands on July 7, 1995 and is headquartered in The Woodlands, TX.

Clinical Trials

Safety and Efficacy of LX4211 With Metformin in Type 2 Diabetes Patients With Inadequate Glycemic Control on Metformin

Phase 2

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: 75 mg LX4211
Drug: 200 mg LX4211
Drug: 400 mg LX4211
Drug: Placebo

First Posted Date: 2011-06-20

Last Posted Date: 2014-10-31

Lead Sponsor: Lexicon Pharmaceuticals

Target Recruit Count: 299

Registration Number: NCT01376557

Locations: 🇺🇸
Lexicon Investigational Site, Virginia Beach, Virginia, United States

A Study to Determine the Pharmacodynamics of LX4211 Relative to Meals in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Schedule A
Drug: Schedule B
Drug: Schedule C
Drug: Schedule D
Drug: Schedule E

First Posted Date: 2011-04-13

Last Posted Date: 2011-05-19

Lead Sponsor: Lexicon Pharmaceuticals

Target Recruit Count: 14

Registration Number: NCT01334242

Locations: 🇺🇸
Lexicon Investigational Site, San Antonio, Texas, United States

A Study to Evaluate the Interaction of LX4211 and Metformin in Healthy Subjects

Phase 1

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: 1000 mg metformin
Drug: 400 mg LX4211

First Posted Date: 2011-02-10

Last Posted Date: 2011-03-30

Lead Sponsor: Lexicon Pharmaceuticals

Target Recruit Count: 18

Registration Number: NCT01292993

Locations: 🇺🇸
Lexicon Investigational Site, San Antonio, Texas, United States

Study of Two Oral Formulations of LX4211 in Patients With Type 2 Diabetes Mellitus

Phase 1

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: 300 mg LX4211 (150 mg tablets)
Drug: 300 mg LX4211 (50 mg tablets)
Drug: 300 mg LX4211 (liquid)

First Posted Date: 2010-08-26

Last Posted Date: 2011-03-30

Lead Sponsor: Lexicon Pharmaceuticals

Target Recruit Count: 15

Registration Number: NCT01188863

Locations: 🇺🇸
Lexicon Investigational Site, San Antonio, Texas, United States

Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome

Phase 2

Completed

Conditions: Carcinoid Syndrome

Interventions: Drug: Telotristat etiprate

First Posted Date: 2010-04-15

Last Posted Date: 2019-03-15

Lead Sponsor: Lexicon Pharmaceuticals

Target Recruit Count: 15

Registration Number: NCT01104415

Locations: 🇬🇧
Lexicon Investigational Site, Manchester, United Kingdom

Study of LX4211 in Subjects With Type 2 Diabetes Mellitus

Phase 2

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: LX4211 Low Dose
Drug: LX4211 High Dose
Drug: Placebo

First Posted Date: 2009-08-19

Last Posted Date: 2011-03-03

Lead Sponsor: Lexicon Pharmaceuticals

Target Recruit Count: 36

Registration Number: NCT00962065

Locations: 🇺🇸
Lexicon Investigational Site, San Antonio, Texas, United States

Study of LX3305 in Subjects With Active Rheumatoid Arthritis on Stable Methotrexate

Phase 2

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: LX3305 low dose
Drug: LX3305 mid dose
Drug: LX3305 high dose
Drug: Placebo

First Posted Date: 2009-05-18

Last Posted Date: 2011-12-15

Lead Sponsor: Lexicon Pharmaceuticals

Target Recruit Count: 208

Registration Number: NCT00903383

Locations: 🇷🇸
Lexicon Investigational Site, Niska Banja, Serbia

Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy

Phase 2

Completed

Conditions: Carcinoid Syndrome

Interventions: Drug: Telotristat etiprate
Drug: Octreotide LAR Depot
Drug: Placebo

First Posted Date: 2009-02-27

Last Posted Date: 2018-12-26

Lead Sponsor: Lexicon Pharmaceuticals

Target Recruit Count: 23

Registration Number: NCT00853047

Locations: 🇺🇸
University of Iowa, Iowa City, Iowa, United States
🇺🇸
Texas Oncology - Weslaco, Weslaco, Texas, United States
🇺🇸
Nebraska Methodist Hospital, Omaha, Nebraska, United States

and more 6 locations

Study of LX3305 and Methotrexate in Subjects With Stable Rheumatoid Arthritis

Phase 1

Completed

Conditions: Rheumatoid Arthritis

Interventions: Drug: LX3305
Drug: LX3305 Placebo
Drug: Methotrexate

First Posted Date: 2009-02-19

Last Posted Date: 2010-06-03

Lead Sponsor: Lexicon Pharmaceuticals

Target Recruit Count: 15

Registration Number: NCT00847886

Locations: 🇺🇸
Metroplex Clinical Research Center, Dallas, Texas, United States

Study of LX1031 in Subjects With Non-Constipating Irritable Bowel Syndrome

Phase 2

Completed

Conditions: Irritable Bowel Syndrome

Interventions: Drug: LX1031 High Dose
Drug: LX1031 Low Dose
Drug: Placebo

First Posted Date: 2008-12-22

Last Posted Date: 2010-12-02

Lead Sponsor: Lexicon Pharmaceuticals

Target Recruit Count: 155

Registration Number: NCT00813098

Locations: 🇺🇸
Affiliated Clinical Research, Las Vegas, Nevada, United States
🇺🇸
Medoff Medical/Vital re:Search, Greensboro, North Carolina, United States
🇺🇸
Consultants for Clinical Research, Cincinnati, Ohio, United States

and more 33 locations

Home Terms & Conditions Privacy Policy